Maria Inmaculada
Heras Fernando
Asociado Ciencias de la Salud
Hospital Universitario 12 de Octubre
Madrid, EspañaPublications in collaboration with researchers from Hospital Universitario 12 de Octubre (9)
2024
-
Cardiac events occurring after allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide. Study conducted on behalf of the GETH-TC
Bone Marrow Transplantation
-
Real-World Experience with Isavuconazole in Allogeneic Stem Cell Transplantation in Spain
Transplantation and Cellular Therapy, Vol. 30, Núm. 10, pp. 1033.e1-1033.e8
2023
-
Results of haploidentical transplant in patients with donor-specific antibodies: a survey on behalf of the Spanish Group of Hematopoietic Transplant and Cell Therapy
Frontiers in immunology, Vol. 14, pp. 1165759
2021
-
Allogeneic Stem Cell Transplantation in Mature T Cell and Natural Killer/T Neoplasias: A Registry Study from Spanish GETH/GELTAMO Centers
Transplantation and Cellular Therapy, Vol. 27, Núm. 6, pp. 493.e1-493.e8
2020
-
Potential Survival Benefit for Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation after Nivolumab Therapy for Relapse/Refractory Hodgkin Lymphoma: Real-Life Experience in Spain
Biology of Blood and Marrow Transplantation, Vol. 26, Núm. 8, pp. 1534-1542
2017
-
Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (with Melphalan, Fludarabine ± Thiotepa) for Allogeneic Transplantation in Relapsed or Refractory Aggressive B Cell Lymphoma: A GELTAMO Trial
Biology of Blood and Marrow Transplantation, Vol. 23, Núm. 1, pp. 53-59
2015
-
Outcome of graft failure after allogeneic stem cell transplant: Study of 89 patients
Leukemia and Lymphoma, Vol. 56, Núm. 3, pp. 656-662
-
Serum galactomannan versus a combination of galactomannan and polymerase chain reaction-based aspergillus DNA detection for early therapy of invasive aspergillosis in high-risk hematological patients: A randomized controlled trial
Clinical Infectious Diseases, Vol. 60, Núm. 3, pp. 405-414
2010
-
Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA study group
Haematologica, Vol. 95, Núm. 4, pp. 589-596